Practice
Featured experience
Goldman Sachs $9.5 billion sale of Boyd Thermal and related business separations
We are advising Goldman Sachs Merchant Banking Division and its portfolio company Boyd on the transactions
REV Group $9 billion merger with Terex
We are advising REV Group on the transaction
Rent the Runway growth recapitalization
We advised Rent the Runway on the transactions
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Clarivate $6.8 billion combination with CPA Global
Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock…
Pattern Energy Operations $700 million senior notes offering
Davis Polk advised Pattern Energy Operations LP and Pattern Energy Operations Inc. on their Rule 144A/Regulation S offering…
GHK Capital Partners acquisition of Hasa and related financing
Davis Polk advised GHK Capital Partners LP on its acquisition of Hasa, Inc. and the related financing arrangements. Davis…
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting…
McDermott International emerges from chapter 11 bankruptcy
Davis Polk advised an ad hoc group (the “Ad Hoc Group”) of prepetition secured term lenders and DIP term lenders in…
BRP Group $175.2 million follow-on offering
Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock,…
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Credo Technology Group Holding $100 million Series D funding round
Davis Polk advised Credo Technology Group Holding Ltd on its private placement of approximately $100 million in shares of…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…